Center For Infectious Diseases Clinical Trials

Trials Currently Enrolling

Mild Disease – considering no antibiotic treatment

• Hypertonic Saline for Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease

Refractory Disease – culture positive despite 6 months therapy

• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101 (Clofazimine Inhalation Suspension) When Added to Guideline-Based Therapy in Participants with Pulmonary Nontuberculous Mycobacterial Infection (Part A) Followed by an Open-Label Extension (Part B) (ICoN-1)

Severe Disease – initiating treatment with IV Amikacin

• Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Drug-Induced Hearing Loss in Patients Receiving Intravenous Amikacin Therapy for Pulmonary Non-Tuberculous Mycobacterium Disease

Bronchiectasis Clinical Trials

• A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Ensifentrine in Subjects with Non-Cystic Fibrosis Bronchiectasis

Vaccine-specific Clinical Trials

• No current studies at this time

Diagnostic Studies

• Evaluation of the VIDAS® TB-IGRA assay for LTBI diagnosis